Insider Selling: Cryoport, Inc. (NASDAQ:CYRX) CFO Sells 1,659 Shares of Stock

Cryoport, Inc. (NASDAQ:CYRX) CFO Robert Stefanovich sold 1,659 shares of the company’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $6.29, for a total transaction of $10,435.11. Following the transaction, the chief financial officer now owns 191,419 shares of the company’s stock, valued at approximately $1,204,025.51. This represents a 0.86 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Robert Stefanovich also recently made the following trade(s):

• On Monday, March 10th, Robert Stefanovich sold 1,256 shares of Cryoport stock. The shares were sold at an average price of $4.88, for a total transaction of $6,129.28.

Cryoport Trading Down 4.9 %

Shares of CYRX traded down $0.32 during midday trading on Tuesday, hitting $6.17. The stock had a trading volume of 728,831 shares, compared to its average volume of 534,310. Cryoport, Inc. has a 1 year low of $4.58 and a 1 year high of $20.11. The firm has a market cap of $307.94 million, a PE ratio of -1.83 and a beta of 1.67. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32. The stock’s 50 day moving average is $6.98 and its 200 day moving average is $7.43.

Cryoport (NASDAQ:CYRX) last announced its earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.09). Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The firm had revenue of $59.53 million during the quarter, compared to analysts’ expectations of $58.71 million. During the same period in the prior year, the company posted ($0.29) EPS. As a group, analysts forecast that Cryoport, Inc. will post -0.99 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CYRX has been the subject of several research reports. Guggenheim initiated coverage on shares of Cryoport in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price objective on shares of Cryoport in a research report on Wednesday, March 5th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Cryoport currently has an average rating of “Moderate Buy” and a consensus target price of $11.50.

Institutional Investors Weigh In On Cryoport

Hedge funds and other institutional investors have recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. raised its stake in shares of Cryoport by 148.7% in the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock valued at $28,000 after acquiring an additional 2,120 shares during the period. Lazard Asset Management LLC purchased a new position in Cryoport in the 4th quarter worth about $51,000. Avanza Fonder AB purchased a new position in Cryoport in the 4th quarter worth about $64,000. Quarry LP purchased a new position in Cryoport in the 4th quarter worth about $69,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Cryoport in the 3rd quarter worth about $82,000. Hedge funds and other institutional investors own 92.90% of the company’s stock.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.